Ticker League

Alto Neuroscience (ANRO) Free Cash Flow Bridge

Pinpoint what moved Alto Neuroscience's free cash flow from TTM through Q1 2025 to TTM through Q1 2026 — operating cash flow shifts and capex changes, each driver sized in dollars.

TTM

FCF YoY

-14.56%

OCF YoY

-17.56%

Capex YoY

-70.35%

FCF Conversion Δ

Free cash flow bridge for Alto Neuroscience (ANRO) — TTM through Q1 2026 vs TTM through Q1 2025

Δ Free cash flow: −$7.99M

FCF bridge breakdown for Alto Neuroscience (ANRO) — TTM through Q1 2026 vs TTM through Q1 2025

  • Prior Free Cash Flow−$54.87M
  • Operating Cash Flow−$9.31M
  • Capital Expenditure$1.32M
  • Free Cash Outflow−$62.86M
Identity check: drivers reconcile to ΔNI within $0.00
Want to see how cash flow is built up?Cash Flow Waterfall

Frequently asked questions

Data & methodology

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation